Orgenesis Inc. Receivables

Receivables of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.

Highlights and Quick Summary

  • Receivables for the quarter ending September 29, 2021 was $19.1 Million (a 10.21% increase compared to previous quarter)
  • Year-over-year quarterly Receivables increased by 488.11%
  • Annual Receivables for 2020 was $3.25 Million (a 59.9% increase from previous year)
  • Annual Receivables for 2019 was $2.04 Million (a -81.82% decrease from previous year)
  • Annual Receivables for 2018 was $11.2 Million (a 0.0% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of Orgenesis Inc.

Most recent Receivablesof ORGS including historical data for past 10 years.

Interactive Chart of Receivables of Orgenesis Inc.

Orgenesis Inc. Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $19.14 $17.36 $11.52
2020 $3.25 $4.28 $4.16 $3.07 $3.25
2019 $2.04 $7.29 $7.14 $6.19 $2.04
2018 $11.19 $4.42 $3.42 $2.55 $11.19
2017 $2.21 $2.28 $3.1 $3.1 $2.21
2016 $2.13 $2.14 $2.14 $2.14
2015 $2.61 $2.62
2014 $0.81 $0.81

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.